



COVID-19 Testing

RT-PCR test validated and offered pursuant to the FDA's EUA
Results available within 24-48 hours of sample receipt

About COVID-19 Testing

The novel coronavirus disease 2019 (COVID-19) has created a global pandemic with a high rate of transmission. This novel disease is caused by a coronavirus called SARS-CoV-2. Nucleic acid amplification testing (NAAT), most commonly with a reverse-transcription polymerase chain reaction (RT-PCR) assay, to detect SARS-CoV-2 RNA from the upper respiratory tract is the preferred initial diagnostic test for COVID-19.^{1,2} Speed and certainty of detection of the SARS-CoV-2 virus within tested populations are key to identifying and isolating potential outbreaks within a community and enabling employees to provide business continuity services.

The COVID-19 Express PCR Test

The **AccessDx COVID-19 PCR test** is the gold standard in accuracy. The COVID-19 PCR diagnostic test quickly identifies the SARS-CoV-2 virus so effective actions can begin sooner.^{1,2} The test allows the identification of current infection in symptomatic individuals as well as asymptomatic individuals with or without consistent symptoms. AccessDx offers a high-quality clinical-grade RT-PCR test that has been made available pursuant to the FDA's Emergency Use Authorization (EUA) for diagnostic testing in CLIA-certified laboratories.

Seamless Integration, Unparalleled Quality

AccessDx is one of the country's leading providers of accurate, quality, and convenient COVID-19 testing. With thousands of clients from a variety of healthcare and workplace landscapes, our clients recognize our commitment to excellence. Our lab tests at a **99.99% accuracy** with our PCR run COVID tests and are able to process **50,000 samples daily**. Our test is highly informative for public health surveillance. The use of two platforms helps ensure continuity of high-volume testing.

AccessDx's dedicated laboratory operations and client success teams are ready to help serve the needs of your organization. In addition to standard laboratory integrations, AccessDx telemedicine partners can evaluate symptomatic employees and facilitate rapid diagnostic testing as necessary.

Testing Statistics

- **Methodology:** Advanced RT-PCR that specifically detects SARS-CoV-2 and other viruses and bacteria
- **Platforms:** Applied Biosystems/ThermoFisher Scientific
- **Specimens/Collection Process:** Nasal (NP) or Oral (OP) swab, provided by AccessDx
- **Turnaround Time:** 24-48 business hours from lab receipt
- **Laboratory Throughput:** 50,000 samples/day (potential)
- **Reimbursement:** Yes - varies with product
- **Telemedicine Options:** Yes via a partner - varies with product and ordering remains at provider discretion
- **Kit Shipping:** Bulk shipments (quantities of 25), returned via individual mailers or via bulk collection based on client operations
- **Cold Chain:** Not required for overnight samples, discuss operations with AccessDx client team.

¹Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 7;69(5):140-146.
²U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). Overview of testing for SARS-CoV-2 (COVID-19).